McCombe William D.
Company insiders · Chief Financial Officer · Cytek Biosciences, Inc.
- Reported transaction lines
- 9
- Buy lines
- 0
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-119
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 213993 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 16,049 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 121811 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 13,051 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 37929 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 12/48 of the total shares underlying the RSU Award vesting on May 18, 2025; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter. | 2026-11-18 | 2026-11-20 | 6,320 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 158193 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 5,401 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 163594 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 16,049 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 147545 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 4,392 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 151937 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 13,051 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 138886 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 2,127 shares/units | SEC 4 |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 141013 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 6,320 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.